Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...

This is the first major breakthrough in 50 years. British researchers have just discovered a new treatment for severe forms ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

With 30% of COPD cases misdiagnosed, experts call for improved diagnostic strategies, better disease classification, and ...

Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

Oklahomans with severe asthma who are insured with BlueCross and BlueShield of Oklahoma (BCBSOK), may have to give themselves life-saving shots at home after a policy change.

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793] Technology appraisal guidance Baloxavir marboxil for treating influenza in babies under 1 year [TSID12141] Technology ...

Baloxavir marboxil for treating influenza in babies under 1 year [TSID12141] Technology appraisal guidance Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794] ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...